KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Amortization - Intangibles (2020 - 2024)

Vir Biotechnology (VIR) has disclosed Amortization - Intangibles for 5 consecutive years, with $18.8 million as the latest value for Q2 2024.

  • Quarterly Amortization - Intangibles fell 18.12% to $18.8 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $82.8 million through Jun 2024, up 18.57% year-over-year, with the annual reading at $87.0 million for FY2023, 209.66% up from the prior year.
  • Amortization - Intangibles hit $18.8 million in Q2 2024 for Vir Biotechnology, down from $21.3 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $23.0 million in Q2 2023 to a low of $11000.0 in Q3 2021.
  • Historically, Amortization - Intangibles has averaged $8.8 million across 5 years, with a median of $2.0 million in 2020.
  • Biggest five-year swings in Amortization - Intangibles: crashed 97.33% in 2021 and later skyrocketed 84736.36% in 2022.
  • Year by year, Amortization - Intangibles stood at $288000.0 in 2020, then crashed by 42.01% to $167000.0 in 2021, then skyrocketed by 9583.83% to $16.2 million in 2022, then rose by 28.22% to $20.7 million in 2023, then fell by 9.11% to $18.8 million in 2024.
  • Business Quant data shows Amortization - Intangibles for VIR at $18.8 million in Q2 2024, $21.3 million in Q1 2024, and $20.7 million in Q4 2023.